Clinical Trial Update: Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating radiotherapy in combination with panitumumab for salivary gland tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chondroid Syringoma
• Mixed Salivary Gland Tumor
• Pleomorphic Adenoma
• Salivary Gland Tumor

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: University of Pittsburgh | Conditions: Adenoma, Pleomorphic, Mixed Salivary Gland Tumor | Phase 2 | Status: WITHDRAWN